« Back
Home /
Bafilomycin A1

Bafilomycin A1

Item no.	HY-100558-5mg
Manufacturer	MedChem Express
CASRN	88899-55-2
Amount	5 mg
Quantity options	100 ug 10mM*1 mL 10 mg 1 mg 250ug 500 ug 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Hepatic Cancer Uterine, Ovarian & Cervical Cancer
Type	Inhibitors
Specific against	other
Purity	99.43
Formula	C35H58O9
Citations	[1]Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56.<br>[2]Lu X, et al. Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med. 2015 Nov;10(5):1829-1834.<br>[3]Ohkuma S, et al. Inhibition of cell growth by bafilomycin A1, a selective inhibitor of vacuolar H(+)-ATPase. In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):862-6.<br>[4]Ohta T, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol. 1998 Jul;185(3):324-30.<br>[5]Mauvezin C, et al. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy. 2015;11(8):1437-1438.<br>[6]Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015;100(3):345-356.<br>[7]Yoshimori T, et al. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266(26):17707-17712<br>[8]Bowman EJ, et al. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A. 1988;85(21):7972-7976.<br>[9]Cattani L, et al. Bafilomycin A1 and intracellular multiplication of Legionella pneumophila. Antimicrob Agents Chemother. 1997;41(1):212-214.<br>[10]Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56.
Smiles	C[C@H]([C@](O[C@@H]1C(C)C)(C[C@@H](O)[C@@H]1C)O)[C@H](O)[C@@H]([C@](OC(/C(OC)=C/C(C)=C\[C@@H](C)[C@@H](O)[C@@H](C)C2)=O)([H])[C@H](/C=C/C=C2\C)OC)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BafA1
Available
Product Description	Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H+-ATPase (V-ATPase) with IC50 values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis[1][2][3].
StorageTemperature	-20°C (Powder, protect from light)
Shipping	Blue Ice
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	622.83
Clinical_Information	No Development Reported
Manufacturers Research Area	Cancer; Infection
Solubility	DMSO : 50 mg/mL (ultrasonic)\|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturers Target	Antibiotic; Apoptosis; Autophagy; Bacterial; Proton Pump
Isoform	Macrolide
Pathway	Anti-infection; Apoptosis; Autophagy; Membrane Transporter/Ion Channel

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100558-5mg-safety-datasheet.pdf